# Food and Drug Administration

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/food-and-drug-administration
Canonical HTML page: https://getbiobrief.com/entity/food-and-drug-administration

## Timeline

- **2026-03-19**: Media Backlash — Health experts and advocacy groups label the bill's scientific claims regarding water pollution as unverified.
- **2026-03-18**: Bill Introduction — Rep. Mary Miller introduces the Clean Water For All Life Act in the House.
- **2026-03-18**: Press Conference — Miller and Kristan Hawkins (Students for Life) present the bill as an environmental protection measure.
- **2026-03-15**: Market Impact — Moderna's valuation remains at roughly 10% of its pandemic-era high amid regulatory uncertainty.
- **2026-02-03**: Refusal to File — Senior regulator Vinay Prasad issues a rare letter refusing to review Moderna's flu vaccine application.
- **2025-12-01**: Grants Rescinded — The White House rescinds hundreds of millions in mRNA research grants as political rhetoric shifts.
- **2025-08-15**: Workaround Supported — FDA officials appear to support Moderna's plan to use data from a smaller trial as a workaround for control group concerns.
- **2024-01-01**: Collaboration Begins — Moderna starts working with the FDA on the design for its mRNA flu vaccine trials.

## Recent coverage (4 stories)

### Only 92 Deals: Big Pharma's TrumpRx Offering Covers Under 12% of Its 800+ Drug Stable
2026-07-16 13:49:27 · Sentiment: Neutral · Impact: 6/10 · Sources: 12

TrumpRx, the Trump administration's drug discount website, has secured voluntary pricing deals on only 92 brand-name drugs—less than 12% of the 800-plus products from 17 major pharmaceutical companies. High-cost therapies for inflammatory diseases, HIV, and cancer are largely excluded, raising doubts about industry's willingness to compromise on pricing without legislation.
Full story: https://getbiobrief.com/story/trumprx-pharma-limited-coverage-92-deals

### FDA to Cut Trial Timelines 6-12 Months as China Takes 50% of Pharma Deals
2026-06-28 14:12:36 · Sentiment: Positive · Impact: 6/10 · Sources: 6

HHS Secretary Kennedy warns that Chinese companies accounted for nearly half of global pharmaceutical licensing deals in 2025, prompting FDA actions to streamline early-stage trials and potentially reduce drug development times by 6 to 12 months. The shift could reshape US biotech competitiveness and investment returns.
Full story: https://getbiobrief.com/story/fda-cut-trial-timelines-china-50-percent-pharma-deals

### GOP Bill Targets Abortion Pill Access via Environmental Water Safety Regulations
2026-03-20 00:33:56 · Sentiment: Negative · Impact: 6/10 · Sources: 3

House Republicans have introduced the Clean Water For All Life Act, a bill that seeks to restrict abortion pill access by framing fetal remains as environmental pollutants. The legislation would mandate 'catch kits' for patients, ban telehealth prescriptions, and impose severe criminal penalties including five-year prison sentences.
Full story: https://getbiobrief.com/story/gop-clean-water-act-abortion-pills

### FDA Regulatory Volatility and Political Shifts Threaten Moderna’s mRNA Pipeline
2026-03-16 00:16:43 · Sentiment: Negative · Impact: 8/10 · Sources: 2

Moderna faces a critical setback after the FDA issued a rare refusal to review its flu vaccine application, signaling a shift in the regulatory and political climate for mRNA technology. This development, coupled with rescinded federal grants and a 90% decline in market value from pandemic peaks, highlights growing friction between the biotech industry and federal oversight.
Full story: https://getbiobrief.com/story/fda-moderna-mrna-regulatory-threat

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.